PhaseBio Pharmaceuticals
IPO
- Headquarters
- Malvern, Pennsylvania
- Employees
- 51–200
- Founded
- 2002
- Business Model
- B2B
- Website
- phasebio.com
- Last Round
- Series DSep 2018
About
PhaseBio Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing novel therapies for serious cardiovascular diseases. The company's lead program was a ticagrelor reversal agent leveraging its proprietary ELP (elastin-like polypeptide) drug delivery platform. PhaseBio filed for Chapter 11 bankruptcy protection in October 2022 after its lead cardiovascular drug candidate failed to meet its primary endpoint in a pivotal clinical trial.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account